Adjunctive Hemoadsorption Therapy with CytoSorb in Patients with Septic/Vasoplegic Shock: A Best Practice Consensus...

Area of Science:

• Critical care medicine
• Immunology
• Biomedical engineering

Background:

• Critically ill patients often exhibit dysregulated host responses leading to organ dysfunction.
• Uncontrolled inflammatory mediator release, or "cytokine storm," contributes to mortality in intensive care units.
• Current therapies lack approved treatments to modulate excessive immune responses and prevent organ failure.

Purpose of the Study:

• To review existing evidence on CytoSorb hemoadsorption therapy.
• To provide consensus-based best practice guidance for its use in vasoplegic shock.
• To identify areas for future research regarding patient selection, timing, and drug interactions.

Main Methods:

• Review of existing literature on CytoSorb hemoadsorption.
• Analysis of clinical outcomes in patients with hyperinflammation.
• Development of consensus-based guidance for clinical application.

Main Results:

• CytoSorb hemoadsorption shows promise in managing hyperinflammation from various causes.
• Ongoing research is needed to optimize patient selection, treatment timing, and duration.
• Potential interactions between CytoSorb and concomitant medications require further investigation.

Conclusions:

• Extracorporeal blood purification, specifically CytoSorb hemoadsorption, is a focus for managing hyperinflammation.
• Further research is essential to refine the application of CytoSorb therapy in critical care.
• Best practice guidance is proposed for CytoSorb use in vasoplegic shock patients.